StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for AZTA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $16.57 | $16.02 | -3.32% | 1.4M |
| 05-18 | $16.12 | $16.24 | +0.74% | 2.3M |
| 05-19 | $16.24 | $17.65 | +8.68% | 1.8M |
| 05-20 | $18.18 | $18.57 | +2.15% | 1.7M |
| 05-21 | $18.32 | $19.54 | +6.66% | 1.4M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Annual 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $293.44M | $148.64M | $593.82M | $434.63M |
Operating Income | $-173.03M | $-7.24M | $-26.84M | $-28.75M |
Net Income | $-176.23M | $-15.43M | $-55.76M | $-106.64M |
EPS (Diluted) | $-3.83 | $-0.34 | $-1.22 | $-2.33 |
Total Assets | $1.90B | $2.07B | $2.06B | $2.02B |
Total Liabilities | $349.21M | $359.60M | $332.60M | $345.98M |
Cash & Equivalents | $234.03M | $336.63M | $279.78M | $270.04M |
Free Cash Flow OCF − CapEx | $20.77M | $14.65M | $38.32M | $44.01M |
Shares Outstanding | 46.09M | 46.02M | 45.86M | 45.78M |
AZTA is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.